Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I respect you tremendously S...I just do not see the light.
Where is VPRO with things now?
1. Motion to dismiss was granted (02/20/2016). Hope or settlement is gone. Viropro has no jurisdiction over Apha Biologics.
2.Without a manufacturing plant, there is no ability to produce biosimilars or anything else, for that matter, any time soon.
3. Merger between VPRO And Novarx implies joint collaboration in furthering clinical research for Lucanix(r), a drug with potential benefits in only a small sub-sample of patients with non-small cell lung carcinoma.
4. Re-initiating conversations with FDA to reach agreement on trial design is rarely a straightforward process.
5. Novarx's pockets are empty. In general, 10s of millions of dollars are required to fund reputable, systematic clinical trials.
6. What would be the incentive for the merger to occur, at all, if there are no funds available from settlement? What would be a good reason for Novarx to partner under these circumstances?
7. All of a sudden Viropro shifts from being a biotech want-to-be to Axxiom Bio...a hedge fund?!?! "Investment instruments"?
8. Axxiom bio is currently embodieded by an amateurish website alla godaddy.com, with a comforting registration license of a full 1 year.
9. How is "AXXIOM" (AXXM) fulfilling SEC requirements for NASDAQ listing as implied on press releases?
10. Where does AXXIOM (VPRO) end and AXXIOM BIO START?
11. What is VIROPRO right now, but a name on a piece of paper.
12. Unless investors have any trust left on AXXIOM BIO to provide the funds to support Novarx research endeavor, there will be no point in merging.
The rest of all small investors will be left out on the call.
Someone asked about the longevity of the website, and this is the information I found.
I do not disagreeing with you. Anyone can search the information. Except, I did not see anyone else to have done so.
The information is public and completely independent from me, who found/post it.
I do not see a need for discourteous exchanges.
A web analysis of domain name registration shows that the site - axxiombio.com - was registered on 07/08/15, and valid for 1 year.
Hosted IP Address:
208.91.197.39
Hosted Country:
United States US
Location Latitude:
30.2672
Location Longitude:
-97.7431
This shell of a website means absolutely nothing. Any amateur could have done a better job building it.
: )
When is VPRO updating investors on the status of purported filings?!?! Too much talk, and no action!!!
Thank you, Shazbat!!
I agree VPRO is not obligated to show anything, as claims stated on press release (10/09) are "forward-looking statements."
However, fulfilling the claim that VPRO is to "complete audit of its [financial statements] by the end of 2015" will show how serious and credible the new Management Team is. After all, it is they who published the these words.
If one thinks about it, this is a significant milestone in the sense that it will demonstrate VPRO's good will, and commitment to investors.
How can anyone expect the stock to continue to climb and investors to continue to invest in a company (that unfortunately, due to its past legacy) has been marred by failure.
If the company fails once again, I stand to lose a tremendous amount of money...more than you can possibly imagine.
I want nothing but for VPRO to be highly successful and to rip my rewards.
By the same token, I refuse to add to the hype of this stock without foundation.
I would not want to contribute to any naive investors losing money as a result of mere puffery. Even if you do not believe me, I would rather lose all my money first.
This is why I expect the new management to live up to the expectations that they themselves have set.
I truly believe that the VPRO core management team is top-performing, and highly qualified, and that Lucanix still has a chance to prove its benefits in certain patient populations.
But...I still need to see those FINANCIAL STATEMENTS before the end of year!!!
Two words: Financial Statements!
Is this the TM for a specific drug?
There seems to be a number of companies with the name Axxion in it.
-Axxiom Consulting
-Axxiom Clothes and Shoes
-Axxiom Manufacturing Inc
Perhaps, VPRO will have to differentiate name by adding something like "Pharmaceutical" or "Therapeutics" to Axxiom (?)
First things first. I want to see VPRO FOLLOWING THROUGH with the claim that it will "complete audit of its [financial statements] by the end of 2015."
C'mon VPRO, you are on the hook. Time to DELIVER!!!
"Viropro indicated that it intends to complete audit of its [financial statements] by the end of 2015, after which it will initiate a process to become current in its periodic filing requirements with the SEC."
http://m.4-traders.com/VIROPRO-INC-104658/news/Viropro-October-9-2015-Viropro-Announces-Appointment-of-Ciro-E-Adams-CPA-LLC-as-New-Audit-21175646/
This is the chance for VPRO to put its money where its mouth is!!
"Viropro indicated that it intends to complete audit of its [financial statements] by the end of 2015, after which it will initiate a process to become current in its periodic filing requirements with the SEC."
http://m.4-traders.com/VIROPRO-INC-104658/news/Viropro-October-9-2015-Viropro-Announces-Appointment-of-Ciro-E-Adams-CPA-LLC-as-New-Audit-21175646/
OMG!!! I was offline for a few days ($0.012), and I returned to find a huge upsurge in stock price ($0.022)!!!!
To all investing in VPRO, do not settle for earnings in the $1000s when you can get $100,000s if you hold on to your stash a little longer!!!!
Do not drag the price down by underselling!!!
No way am I selling any of mine. My sense is 0.05-0.10 is around the corner!!
Some companies, like Fidelity and Charles Schwab, place restrictions on the trade of OTC stocks.
Some companies include a disclaimer with an option to accept risk, then, you can trade. I do not recall if Fidelity provides this option.
I use the two companies above, but I have switched a large chunk of my stocks to E-Trade, which I like for its flexibility.
Could not agree more!!
; )
Do you mean Miss?!
Wow!!! Is VPRO already hiring?!?!?!?
Access hyperlink, if you click on the button that reads, "view jobs for this company [Viropro]," the first job posting that appears is this:
http://www.biospace.com/company_profile.aspx?CompanyId=1001953
VP of Cancer Drug Research
San Francisco Bay Area, CA
NOTE: Biotecher is a pharmaceutical recruiting firm.
For direct access to posting click on this hyperlink. http://www.biospace.com/jobs/job-listing/vp-of-cancer-drug-research-leading-in-vitro-biology-and-in-vivo-pharmacology-351104
The VPRO website has already incorporated a (password protected) hyperlink on the menu for NovaRx?!?!
Are they getting closer to finalizing the merger?!
Click on main menu, under "Private."
http://www.viropro.net/
The FDA clears Zogenix's (NASDAQ:ZGNX) Investigational New Drug (IND) application for lead product candidate ZX008.
The approval allows the company to initiate its Phase 3 program for the adjunctive treatment of seizures in children with Dravet syndrome, a rare and catastrophic form of intractable epilepsy that begins in infancy.
Full story: Zogenix cleared to start late-stage studies of lead product candidate in Dravet http://www.seekingalpha.com/news/2982746
It will happen!! I am hoping for $.10!!
All press releases from any company in the pharmaceutical/biotechnology industry include this statement. This is to comply with federal law, SEC.
This is a press release about Pfizer selected at random. But, you may want to corroborate things on your own.
http://www.pfizer.com/news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_initiate_two_phase_iii_studies_of_investigational_immunotherapy_avelumab_in_advanced_gastric_and_gastro_esophageal_junction_cancers
These Biotechs Will Be a Holiday Treat For Investors - Yahoo Finance
Propanc Health Group (PPCH) recently completed animal efficacy studies. During the course of these studies, PPCH discovered a new target therapeutic dose range using proenzymes for treating cancer. The company filed a patent application in support of this discovery earlier this month.
Full story: http://finance.yahoo.com/news/biotechs-holiday-treat-investors-173800590.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANlbW1oZ2s5YjZ0ZzA5BGcDZFhWcFpEeHVjejVtWkRGbU1UbGxZeTFoTlRFMExUTXhOVEl0T0RnMVpDMHdNR0V5TjJFNU1URXpZalU4Wm1sbGJHUStjSEJqYUE9PQRsYW5nA2VuLVVTBG9yaWdfbGFuZwNlbi1VUwRvcmlnX3JlZ2lvbgNVUwRwb3MDMARyZWdpb24DVVMEc3ltYm9sA1BQQ0g-?.tsrc=applewf
Insider Money, December 12
ZGNX has 25 hedge funds with bullish positions and the amount invested in stocks is $158 million.
Relative to other companies with bullish positions (ie., NEOS, PBPB, CMTL), ZGNX might be a better candidate to consider a long position.
Full story: http://www.insidermonkey.com/blog/newbridge-bancorp-nbbc-hedge-funds-are-snapping-up-400098/?singlepage=1
SEATTLE, Dec. 14, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales milestones for TRISENOX® (arsenic trioxide). TRISENOX was acquired from CTI BioPharma by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under which CTI BioPharma is eligible to receive up to an additional $70 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.
Full article: http://finance.yahoo.com/news/cti-biopharma-receives-10-million-063000863.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANhazFldDcxYjZ0ZWNoBGcDZFhWcFpEeHVjejR4WldaaE0yWTROQzAwTkRJMkxUTmlNV0V0T1dFMU15MDJOV1V3TW1Jd05UVm1Oak04Wm1sbGJHUStZM1JwWXc9PQRsYW5nA2VuLVVTBG9yaWdfbGFuZwNlbi1VUwRvcmlnX3JlZ2lvbgNVUwRwb3MDMARyZWdpb24DVVMEc3ltYm9sA0NUSUM-?.tsrc=applewf
I am counting the minutes!!
It appears as though the pieces of the puzzle are coming together...!!
There is a long history in terms of the professional relationship between Fakhrai and Royston.
"Ivor Royston, the former CEO of Sidney Kimmel, who first hired Fakhrai to head its gene therapy unit, described him as a sharp scientist with “a passion to do something to cure cancer."
Royston is not a stranger to NovaRx either. "Habib feels strongly that he has a new weapon for the treatment of cancer,” said Royston, now a partner in San Diego venture capital firm Forward Ventures. “He's passionate about the science and about helping patients" (1996).
http://www.utsandiego.com/uniontrib/20060609/news_1b9novarx.html
Moreover, Fakhrai and Royston have collaborated as coauthors in the publication of numerous research studies.
And, now Royston has joined the board of VPRO around the time VPRO is intending to merge with NovaRx? Hmmmmmmm!!!!
Take a look at the potential of Lucanix if future phase 3 clinical are designed correctly.
"Data from a study of 75 patients with advanced stages of lung cancer showed that 43 percent of them were alive two years after receiving NovaRx's drug, dubbed Lucanix. That's four times the survival rate seen with chemotherapy, the current standard of care."
This could become an important treatment in patients with non-small cell lung cancers. The value proposition of this drug might be huge.
Yessssss!!!!!
Based on the science, phase 2 trials, and partial evidence from phase 3 clinical trials, I think there is real hope for Lucanix. I believe in this product.
I am not against any particular individual, I am simply skeptical of the argument that JM has the level of gravitas some people seem to attribute to him.
NovaRx publicly acknowledged they needed $25 M to continue the trials. In the biotech world, relatively speaking, 25 M is a meager amount of money.
Where are all the connections and support of the business community JM presumably has? Why has NovaRx not been able to secure additional capital to fund their efforts a bit longer? Why has big pharma not shown any interest in getting involved? Why is there not a bidding war for this company? Why are they willing to surrender their only asset to another floundering, cash-strapped company?
I believe that combining the brain power and professional experience of the real experts in each company can be incredible. Combining strengths is likely the best chance they have to succeed. And, I am betting full-heartedly on their success. No question about it.
I am with you.
In my mind, this has no bearing in VPRO's future success.
Fact: NovaRx phase 3 clinical trial of Lucanix has already failed due to methodological issues. This is precisely what has made NovaRx vulnerable to the reverse merger.
On the other hand, secondary analysis of data showed significant benefits in a subpopulation of patients.
In my opinion, if merger occurs, careful refinement in the design and implementation of future clinical trials is were the potential success of VPRO lies.
Fact: The 35 M were invested by the Murdocks in 2007-2008 in the hopes phase 3 trial would succeed. As stated above, these hopes are long gone, and no additional funds seem to have been committed for further trials.
David Murdock is 92 years old, and unlike his father, Justin Murdock (NovaRx's Chairman of the Board) does not have a great level of credibility in the businesses world. According to Forbes, Murdock Jr is a college drop out who enjoys his celebrity and playboy status.
If acquired by VPRO, Lucanix has the potential to be advanced as a real treatment for patients with non-small cell lung cancer.
I think people seriously interested in investing in VPRO need to make a well informed decision. I am not referring to those who wish to make few 1000th of a dollar in each trade. I am talking about those, who like me, are in it for an all-or-none type of gamble.
Hyperbole only goes so far in hyping this stock.
Realizing the merger and securing funds for additional clinical trials could change the lives of many committed investors.
PwC probably arguing in favor of a summary judgment against VPRO's jurisdiction over AB.
I do not think this will happen, but judge needs to rule here for a trial...enough of this back and forth!!
Oh, oh, back to 1B Mkt cap...OK, $5.00 on IPO...
In September of this year, prior to Cortendo's changing name (now SBBP) and transitioning to NASDAQ exchange, it underwent an 11:1 reverse split. Price was adjusted from around $1.65 pre IPO to $12.00 on IPO (price has slid since to about $6.00).
I hate crazy speculation, but at the same time I cannot help it!! A 10:1 for AXXM at $10.00 on IPO would be great!
In the past, I have generally seen reputable biotech start ups hover around the $300-500 M market cap mark, close to IPO outside of the OTC exchange. Of course, purely speculative, but this would be my guess for AXXM as well.
You may be right. I'll keep positive hoping for the best!!